Share-based Payment Arrangement, Expense of Tenaya Therapeutics, Inc. from 30 Jun 2020 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Tenaya Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 31 Dec 2025.
  • Tenaya Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $2,746,000, a 27% decline year-over-year.
  • Tenaya Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $13,046,000, a 21% decline year-over-year.
  • Tenaya Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $13,046,000, a 21% decline from 2024.
  • Tenaya Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $16,502,000, a 7.8% increase from 2023.
  • Tenaya Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $15,309,000, a 34% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Tenaya Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $13,046,000 $2,746,000 -$1,014,000 -27% 01 Oct 2025 31 Dec 2025 10-K 11 Mar 2026 2025 FY
Q3 2025 $14,060,000 $2,934,000 -$973,000 -25% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $15,033,000 $3,635,000 -$976,000 -21% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $16,009,000 $3,731,000 -$493,000 -12% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $16,502,000 $3,760,000 -$189,000 -4.8% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2026 2025 FY
Q3 2024 $16,691,000 $3,907,000 -$108,000 -2.7% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $16,799,000 $4,611,000 +$780,000 +20% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $16,019,000 $4,224,000 +$710,000 +20% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $15,309,000 $3,949,000 +$762,000 +24% 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $14,547,000 $4,015,000 +$841,000 +26% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $13,706,000 $3,831,000 +$819,000 +27% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $12,887,000 $3,514,000 +$1,420,000 +68% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $11,467,000 $3,187,000 +$2,139,000 +204% 01 Oct 2022 31 Dec 2022 10-K 18 Mar 2024 2023 FY
Q3 2022 $9,328,000 $3,174,000 +$2,206,000 +228% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $7,122,000 $3,012,000 +$2,510,000 +500% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $4,612,000 $2,094,000 +$1,662,000 +385% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $2,950,000 $1,048,000 01 Oct 2021 31 Dec 2021 10-K 08 Mar 2023 2022 FY
Q3 2021 $968,000 +$770,000 +389% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $502,000 +$317,000 +171% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $432,000 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q3 2020 $198,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $185,000 01 Apr 2020 30 Jun 2020 10-Q 08 Sep 2021 2021 Q2

Tenaya Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $13,046,000 -$3,456,000 -21% 01 Jan 2025 31 Dec 2025 10-K 11 Mar 2026 2025 FY
2024 $16,502,000 +$1,193,000 +7.8% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2026 2025 FY
2023 $15,309,000 +$3,842,000 +34% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $11,467,000 +$8,517,000 +289% 01 Jan 2022 31 Dec 2022 10-K 18 Mar 2024 2023 FY
2021 $2,950,000 +$2,209,000 +298% 01 Jan 2021 31 Dec 2021 10-K 08 Mar 2023 2022 FY
2020 $741,000 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.